Heparin Treatments for Acute Coronary Syndrome
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2006 Mar 1;73(5):890.
Clinical Question: Is the low-molecular-weight heparin (LMWH) enoxaparin (Lovenox) more effective than unfractionated heparin in the management of acute coronary syndromes?
Setting: Inpatient (any location) with outpatient follow-up
Study Design: Randomized controlled trial (double-blinded)
Synopsis: Previous studies show that LMWH and unfractionated heparin are similarly effective at 30 days of follow-up in the treatment of high-risk patients with acute coronary syndromes. The investigators reported the follow-up for more than 96 percent of 9,978 patients with acute coronary syndromes at six months and one year. The patients received enoxaparin or unfractionated heparin (uncertain allocation concealment) with standard therapy, including aspirin and clopidogrel (Plavix) when indicated. All analyses are based on intention to treat. All-cause death at one year, nonfatal myocardial infarction, and rehospitalization occurred at a similar rate in patients receiving enoxaparin and unfractionated heparin.
Bottom Line: The LMWH enoxaparin is no more effective than unfractionated heparin in the treatment of patients with acute coronary syndromes. (Level of Evidence: 1b)
Mahaffey KW, et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin. Outcomes at 6 months and 1 year in the SYNERGY trial JAMA. November 23, 2005;294:2594–600
Used with permission from Slawson D. Enoxaparin = heparin for acute coronary syndrome (SYNERGY). Accessed online December 27, 2005, at: http://www.InfoPOEMs.com.
Want to use this article elsewhere? Get Permissions